Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 23, 2017

Infinity reports positive preclinical / Phase I data of IPI-549 for treatment of solid tumours

Infinity Pharmaceuticals has reported positive results from preclinical and Phase I studies of IPI-549 at the Keystone Symposia Conference.

Infinity Pharmaceuticals has reported positive results from preclinical and Phase I studies of IPI-549 at the Keystone Symposia Conference.

IPI-549 is an investigational oral immuno-oncology drug designed to treat advanced solid tumours by selectively inhibiting phosphoinositide-3-kinase-gamma (PI3K-gamma).

The data from preclinical study indicated that IPI-549 effects the myeloid cells and remodels the immune-suppressive tumour microenvironment, resulting in elimination of the resistance to immune checkpoint blockade.

The results from the Phase I study conducted in nine patients showed positive safety, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy.

"The results from the Phase I study conducted in nine patients showed positive safety, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy."

The Phase I study involves the evaluation of IPI-549 as a monotherapy and in combination with a PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumours.

Infinity Pharmaceuticals biology and translational science vice-president Jeffery Kutok said: "The data presented suggest that targeting PI3K-gamma by IPI-549 within immune-suppressive myeloid cells in the tumour microenvironment could offer a unique way to both enhance the activity of checkpoint inhibition in sensitive tumours, as well as to overcome tumour resistance to checkpoint inhibition.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

"Infinity is excited to be at the forefront of developing a potentially transformative approach within immuno-oncology, and we look forward to reporting additional data from our Phase I study of IPI-549 later this year."

The firm intends to further base its Phase I study in patients with non-small-cell lung cancer (NSCLC), melanoma, and squamous cell carcinoma of the head and neck (SCCHN), on the data from the preclinical study.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU